BD Syringes and Needles
REF: Refer to Table 1
Type of Action: Advisory
Attention: Clinical Engineering Managers, Clinical Personnel, Risk Managers
This letter contains important information which requires your attention.
BD is issuing this Field Safety Notice for the BD Syringes and Needles listed in Table 1 below to advise of an added caution.
Table 1: List of impacted products
309628 – BD 1ml Syringe Luer-Lok™ Tip
303172 – BD Plastipak™ 1ml Luer
305211 – BD Blunt Fill Needle with Filter 18G x 1 1/2 (1.2mm x 40mm) (5μm)
302809 – BD Microlance™ 3 30G x ½” 0,3 x 13mm
304000 – BD Microlance™ 3 30G x ½” 0,3 x 13mm
Description of the Problem
It has been identified through post-market surveillance reviews that a caution should be added to the Instructions for Use (IFU) for the products listed in Table 1 above.
Note: The above listed products are not to be used for ocular medications due to the increased potential for adverse eye conditions, as outlined below.
This Field Safety Notice is providing the following caution and BD recommends it be applied when using the product.
Intraocular use is not validated by BD
BD has become aware that when syringes and needles are used for intraocular injections, the potential exists for “floaters” in patients’ eyes which are believed to be due to silicone. (Note: Syringes and needles manufactured by BD have silicone applied to the inside of the barrels to provide lubrication for the plunger stopper, allowing it to move easily). The potential hazard is deposition of silicone oil (SO) droplets in the vitreous. The potential harm could be symptomatic “floaters” in the patient’s field of vision which, normally, are tolerable and resolve over a few months. However, if sufficiently bothersome, floaters may lead to a vitrectomy for their removal.
BD became aware of other potential risks associated with intraocular injections, such as endophthalmitis (inflammation of the interior of the eye), which may be associated with failure modes not previously identified by BD.
To reduce this risk of silicone floaters and inflammation or irritation that may occur, HCPs should only use the syringes and needles provided with ocular medications that are specifically designed and labelled for intravitreal injection.
Following reports of use in intra-ocular procedures BD is updating the IFU and future product being shipped by BD will contain the caution.
Advice on actions to be taken by the user:
Should you have any questions or experience any issues associated with the product or issue described in this Field Safety Notice, please contact BDUKFieldAction@bd.com. BD has notified the appropriate regulatory agencies of these actions.
BD is committed to ensuring that safe and effective product is available to customers and this Field Safety Notice is taken with due consideration of this commitment.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.